Franck Bonnetain

18.6k total citations · 5 hit papers
288 papers, 11.2k citations indexed

About

Franck Bonnetain is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Franck Bonnetain has authored 288 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 183 papers in Oncology, 102 papers in Pulmonary and Respiratory Medicine and 66 papers in Surgery. Recurrent topics in Franck Bonnetain's work include Colorectal Cancer Treatments and Studies (71 papers), Pancreatic and Hepatic Oncology Research (43 papers) and Gastric Cancer Management and Outcomes (43 papers). Franck Bonnetain is often cited by papers focused on Colorectal Cancer Treatments and Studies (71 papers), Pancreatic and Hepatic Oncology Research (43 papers) and Gastric Cancer Management and Outcomes (43 papers). Franck Bonnetain collaborates with scholars based in France, Belgium and United States. Franck Bonnetain's co-authors include Laurent Bedenne, Olivier Bouché, Benoist Chibaudel, C. Mariette, Thierry André, Jean‐Pierre Gérard, Denis Pezet, Pascal Hammel, Thierry Conroy and Christophe Louvet and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Franck Bonnetain

281 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203

2006 1.3k citations Thierry Conroy, Franck Bonnetain et al. profile →
Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102

2007 868 citations Laurent Bedenne, Pierre Michel et al. profile →
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

2016 685 citations Pascal Hammel, F. Huguet et al. profile →
Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer

2019 434 citations Tienhan Sandrine Dabakuyo‐Yonli, Franck Bonnetain et al. profile →
Nomograms for Predicting Local Recurrence, Distant Metastases, and Overall Survival for Patients With Locally Advanced Rectal Cancer on the Basis of European Randomized Clinical Trials

2011 386 citations Franck Bonnetain et al. profile →

Peers

Countries citing papers authored by Franck Bonnetain

Since Specialization

Citations

This map shows the geographic impact of Franck Bonnetain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franck Bonnetain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franck Bonnetain more than expected).

Fields of papers citing papers by Franck Bonnetain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franck Bonnetain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franck Bonnetain. The network helps show where Franck Bonnetain may publish in the future.

Co-authorship network of co-authors of Franck Bonnetain

This figure shows the co-authorship network connecting the top 25 collaborators of Franck Bonnetain. A scholar is included among the top collaborators of Franck Bonnetain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franck Bonnetain. Franck Bonnetain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma 2021 ·International Journal of Radiation OncologyBiologyPhysics ·Antoine Schernberg, Déwi Vernerey, David Goldstein, Jean‐Luc Van Laethem, Bengt Glimelius, Paul Van Houtte, Franck Bonnetain, Christophe Louvet, Pascal Hammel, F. Huguet	7
2	Longitudinal analysis of health-related quality of life in cancer clinical trials: methods and interpretation of results 2020 ·Quality of Life Research ·Caroline Mollévi, (unknown), C. Bourgier, Thierry Conroy, Bruno Chauffert, Mohamed Hebbar, William Jacot, Béata Juzyna, Hélène de Forges, Sophie Gourgou, Franck Bonnetain, Célia Touraine, Amélie Anota	10
3	Ethical leadership, professional caregivers' well-being, and patients' perceptions of quality of care in oncology 2018 ·European Journal of Oncology Nursing ·Nicolas Gillet, Evelyne Fouquereau, Hélène Coillot, Franck Bonnetain, Sophie Dupont, L. Moret, Amélie Anota, Philippe Colombat	18
4	The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer 2017 ·Cancer ·Florian Manneville, Christine Rotonda, Thierry Conroy, Franck Bonnetain, Françis Guillemin, Abdou Y. Omorou	15
5	Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study) 2017 ·Annals of Oncology ·Stéfano Kim, Éric François, (unknown), Emmanuelle Samalin, Farid El Hajbi, Nabil Baba-Hamed, Sarah Dumont, Simon Pernot, D. Peiffert, François Ghiringhelli, Olivier Bouché, Jérôme Desrame, Mustapha Zoubir, Aurélie Parzy, Denis Smith, Christelle de la Fouchardière, Bruno Buecher, V. Vendrely, Franck Bonnetain, Christophe Borg	1
6	Pratiques et attitudes des médecins généralistes de Besançon vis-à-vis de la vaccination anti-HPV 2016 ·HAL (Le Centre pour la Communication Scientifique Directe) ·(unknown), Christiane Mougin, Jean‐Luc Prétet, Aurélia Meurisse, Franck Bonnetain, (unknown)	7
7	An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma 2016 ·BMJ Open ·Amélie Anota, Mathieu Boulin, Tienhan Sandrine Dabakuyo‐Yonli, Patrick Hillon, Jean–Pierre Cercueil, Anne Minello, Jean–Louis Jouve, Xavier Paolettí, Laurent Bedenne, Boris Guiu, Franck Bonnetain	11
8	Methodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical review 2016 ·BMC Cancer ·Frédéric Fiteni, Amélie Anota, Virginie Westeel, Franck Bonnetain	31
9	Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma 2015 ·Cancer Epidemiology Biomarkers & Prevention ·Marine Jary, Déwi Vernerey, Thierry Lecomte, Erion Dobi, François Ghiringhelli, Franck Monnien, Yann Godet, Stéfano Kim, Olivier Bouché, Serge Fratté, Anthony Gonçalvès, Julie Léger, (unknown), Olivier Adotévi, Franck Bonnetain, Christophe Borg	16
10	In the Era of Genomics, Should Tumor Size Be Reconsidered as a Criterion for Neoadjuvant Chemotherapy? 2015 ·The Oncologist ·Xavier Pivot, Laura Mansi, L. Chaigneau, Philippe Montcuquet, Antoine Thiery-Vuillemin, Fernando Bazán, Erion Dobi, (unknown), (unknown), (unknown), (unknown), Farid Jamshidian, Phillip G. Febbo, Christer Svedman, Sophie Paget‐Bailly, Franck Bonnetain, (unknown)	19
11	Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer 2014 ·Cancer Chemotherapy and Pharmacology ·Marine Jary, François Ghiringhelli, Marion Jacquin, Francine Fein, Thierry Nguyen, D Cléau, Virginie Nerich, (unknown), P Mathieu, Séverine Valmary‐Degano, Laurent Arnould, (unknown), Najib Lamfichekh, Serge Fratté, Sophie Paget‐Bailly, Franck Bonnetain, Christophe Borg, Stéfano Kim	6
12	Projecting Event-Based Analysis Dates in Clinical Trials: An Illustration Based on the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) Collaboration. Projecting Analysis Dates for the IDEA Collaboration 2014 ·SHILAP Revista de lepidopterología ·Lindsay A. Renfro, Axel Grothey, James Paul, Irene Floriani, Franck Bonnetain, Donna Niedzwiecki, Takeharu Yamanaka, Ioannis Souglakos, Greg Yothers, Daniel J. Sargent	1
13	Endpoints in cancer clinical trials 2014 ·Journal of Visceral Surgery ·Frédéric Fiteni, Virginie Westeel, Xavier Pivot, Christophe Borg, Déwi Vernerey, Franck Bonnetain	81
14	Comparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study 2014 ·Health and Quality of Life Outcomes ·Amélie Anota, (unknown), M. Savina, (unknown), S. Gourgou-Bourgade, Franck Bonnetain, Caroline Mollévi	13
15	Statistical challenges of quality of life and cancer: new avenues for future research 2013 ·Expert Review of Pharmacoeconomics & Outcomes Research ·Laurent Boyer, Karine Baumstarck, Pierre Michel, Mohamed Boucékine, Amélie Anota, Franck Bonnetain, Joël Coste, Bruno Falissard, Alice Guilleux, Jean-Benoît Hardouin, Anderson Loundou, Mariette Mercier, Mounir Mesbah, Alexandra Rouquette, Véronique Sebille, Mathilde G. E. Verdam, Badih Ghattas, Françis Guillemin, Pascal Auquier	7
16	DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma 2013 ·Annals of Oncology ·Stéfano Kim, Marine Jary, Luigi Mansi, (unknown), (unknown), Martin Demarchi, Trang Huyen Thi Nguyen, Alexandre Kaliski, Éric Delabrousse, Franck Bonnetain, (unknown), Jean-François Bosset, Séverine Valmary‐Degano, Christophe Borg	32
17	Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy 2011 ·Clinical Cancer Research ·Aziz Zaanan, Jean–François Fléjou, Jean‐François Emile, (unknown), Peggy Cuillière-Dartigues, David Malka, Cédric Lecaille, Pierre Validire, Christophe Louvet, Philippe Rougier, Aimery de Gramont, Franck Bonnetain, Françoise Praz, Julien Taı̈eb	64
18	Factors correlated with fatigue in breast cancer patients before, during and after adjuvant chemotherapy: The FATSEIN study 2010 ·Contemporary Clinical Trials ·Christine Rotonda, F. Guillemin, Franck Bonnetain, Thierry Conroy	12
19	Prise en charge des adénocarcinomes de la jonction œsogastrique résécables : quel traitement périopératoire ? 2008 ·Cancer/Radiothérapie ·G. Créhange, Franck Bonnetain, Bruno Chauffert, Paul Rat, Laurent Bedenne, P. Maingon	6
20	Population-based study of breast cancer survival in Cote d’Or (France): prognostic factors and relative survival 2007 ·Annals of Oncology ·(unknown), Franck Bonnetain, Patrick Roignot, Marie‐Laure Poillot, Gilles Chaplain, (unknown), Guy Hédelin, Patrick Arveux	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact